Prognostic impact of genetic abnormalities in patients with B-NHL after CAR19/22 T-cell cocktail therapy. PFS (A) and OS (B), according to risk-stratified genetic subtypes. Of the patients with MYC rearrangements (MYCr), including patients with MYC and BCL2 or BCL6 rearrangements (HGBL DH), the median PFS and median OS were NR. Two patients with HGBL DH further received auto-HSCT and second-round CAR T-cell cocktail infusion. Of the patients with del(17p) or TP53 mutation, the median PFS was 8.8 months (95% CI, 1.0-NR), and the median OS was 14.5 months (95% CI, 2.7-NR). Of the patients without the above-mentioned aberrations (W/O), the median PFS was 4.6 months (95% CI, 3.0-NR), and the median OS was 14.5 months (95% CI, 4.6-NR).